Several clinical trials have explored CAR-T therapies targeting multiple antigens in AML, and preliminary results suggest that targeting broadly expressed antigens (such as CD123, CD38, CLL-1, NKG2D-L or CD33) or less common ones (such as CD7 and CD19) could lead to clinical responses in this difficult-to-treat population. The gene discussed is CD33; the disease is acute myeloid leukemia.